Associated tags: Engineering, HER2, Drug development, Conjugation, Zymeworks, Patient, Biotechnology, Health, Pharmaceutical, Inc., Research, Pharmaceutical industry, Clinical Trials, Oncology, NYSE
Locations: MIDDLETOWN, DE, US, UNITED STATES, BRITISH COLUMBIA, CALIFORNIA
Transfer,
Breast cancer,
FDA,
The Transfer Agreement,
Food,
BTC,
Research,
Trastuzumab,
MAA,
Insurance,
Jazz Pharmaceuticals,
MSAT,
Abstract,
IND,
ASCO,
Disease,
CD28,
HER2,
Tax,
ADC,
Three Months,
Patient,
Society,
EMA,
Bone marrow,
BLA,
Standard of care,
AACR,
Autoimmunity,
European Medicines Agency,
Pharmaceutical industry In May 2024, our partner Jazz guided that their plans to submit a marketing authorization application (MAA) to the European Medicines Agency (EMA) for zanidatamab in BTC are proceeding.
Key Points:
- In May 2024, our partner Jazz guided that their plans to submit a marketing authorization application (MAA) to the European Medicines Agency (EMA) for zanidatamab in BTC are proceeding.
- Financial Results for the Three Months Ended March 31, 2024
Revenue was $10.0 million for the three months ended March 31, 2024 compared to $35.6 million for the same period in 2023.
- Other income, net increased by $1.9 million for the three months ended March 31, 2024 compared to the same period in 2023.
- Net loss for the three months ended March 31, 2024 was $31.7 million compared to $24.4 million loss for the same period in 2023.
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its first quarter 2024 financial results after market close on May 2, 2024.
Key Points:
- VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its first quarter 2024 financial results after market close on May 2, 2024.
- Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 2, 2024 at 4:30 pm Eastern Time (ET).
Well,
Small-cell carcinoma,
Therapeutic index,
Glomus tumor,
Endometrial cancer,
Survival,
Environment,
Service provider,
Trichloroethylene,
Patient,
Primate,
Triple-negative breast cancer,
Lead,
Zymeworks,
3D,
Standard of care,
Cancer,
TAA,
Spacecraft,
Lung cancer,
IND,
CD3,
DLL3,
AACR,
Workflow,
Antibody,
TCE,
CD28,
Therapy,
Stomach,
ADC,
Vaccine The compelling preclinical activity profile supports ZW191 development across multiple tumor types, including FRα-high/mid/low ovarian cancers and other FRα-expressing indications, including non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer.
Key Points:
- The compelling preclinical activity profile supports ZW191 development across multiple tumor types, including FRα-high/mid/low ovarian cancers and other FRα-expressing indications, including non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer.
- An investigational new drug (IND) submission or foreign equivalent is planned for 2024.
- Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with a poor prognosis and high unmet medical need2.
- Displays no cross-linking of T cells and exhibits obligate cis T cell binding of CD28, requiring co-engagement of CD3.
AbbVie,
Inflammation,
Growth,
AstraZeneca,
Astex Pharmaceuticals,
Trinity College,
Novartis,
Patient,
Research,
Standard of care,
University,
Head,
Trinity College Dublin,
Therapy,
Cancer,
Drug development,
Amgen,
Marketing,
Pharmaceutical industry Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and strengthen the Board governance and oversight required for the next stage of the Company’s development and growth,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.
Key Points:
- Gallagher is the sixth director to join our board of directors in the past twelve months as we continue to refresh and strengthen the Board governance and oversight required for the next stage of the Company’s development and growth,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.
- Dr. Gallagher has directly led or overseen multiple medical product approvals globally, including biologics and small molecules, across several therapeutic areas.
- Before joining Syndax Pharmaceuticals in 2023, Dr. Gallagher was Head of Development and Chief Medical Officer of AbbVie.
- Dr. Gallagher was also appointed to serve as a member of the research and development committee of the board of directors.
Retrieved on:
Wednesday, March 27, 2024
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
Key Points:
- VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
23rd Annual Needham Virtual Healthcare Conference: Zymeworks’ management will participate in virtual one-on-one meetings and present on April 11th at 11:45 am Eastern Time (ET).
- Canaccord Genuity Horizons in Oncology Virtual Conference: Zymeworks’ management will participate in virtual one-on-one meetings and a panel discussion on April 15th at 3:00 pm ET.
- Stifel Virtual Targeted Oncology Days Conference: Zymeworks’ management will participate in virtual one-on-one meetings and present on April 16th at 12:30 pm ET.
- 2024 Bloom Burton & Co. Healthcare Investor Conference: Zymeworks’ management will participate in one-on-one meetings and present on April 16th at 2:00 pm ET.
Senior,
Research,
Fulvestrant,
Sale,
University,
NBI,
Tax,
MSAT,
Plasma,
CD28,
BTC,
NASDAQ Biotechnology Index,
Pain,
Rat,
BLA,
Standard of care,
Antibody,
HER2,
MD Anderson Cancer Center,
Abstract (summary),
GAAP,
Therapy,
Carcinoma,
Abstract,
Depreciation,
Partnership,
Camptothecin,
Manuscript,
Conference,
Partner,
IND,
NMPA,
Jazz Pharmaceuticals,
PFS,
BeiGene,
FDA,
Spacecraft,
Pembrolizumab,
CDX,
ADC,
OS,
Society,
Patient,
Pharmaceutical industry Financial Results for the Year Ended December 31, 2023
Key Points:
- Financial Results for the Year Ended December 31, 2023
Revenue was $76.0 million in 2023 compared to $412.5 million in 2022.
- Higher interest income in 2023 was due to income earned on higher cash resources and at higher rates of return in 2023.
- “We are happy to report a continued reduction of our operating cash burn and operating losses during 2023 compared to 2022,” said Chris Astle, Ph.D., Senior Vice President and Chief Financial Officer of Zymeworks.
- Reconciliations between historical GAAP and non-GAAP information are contained at the end of this press release following the accompanying financial data.
Strong preclinical activity across multiple FRα-expressing indications for ZW191, a FRα-targeting antibody-drug conjugate
Key Points:
- Strong preclinical activity across multiple FRα-expressing indications for ZW191, a FRα-targeting antibody-drug conjugate
VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced acceptance of five abstracts for poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place at the San Diego Convention Center in San Diego, CA from April 5-10, 2024.
- “Our team is especially excited to participate in AACR this year to highlight some recent advancements in the development of our next generation antibody-drug conjugate and multispecific antibody therapeutics,” said Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks.
- “Five abstracts being accepted underscores the strong progress we continue to make in advancing multiple development programs based on our proprietary engineering platforms and integrated technologies.”
Title: TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 costimulation, engineered to improve responses in the treatment of solid tumors
Retrieved on:
Tuesday, February 27, 2024
VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
Key Points:
- VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
TD Cowen 44th Annual Health Care Conference: Zymeworks’ management will participate in one-on-one meetings and present on March 6th at 11:10 am Eastern Time (ET) in Boston, MA.
- Barclays 26th Annual Global Healthcare Conference: Zymeworks’ management will participate in one-on-one meetings and a fireside chat on March 14th at 11:45 am ET in Miami, FL.
Retrieved on:
Wednesday, February 14, 2024
VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its fourth quarter 2023 financial results after market close on March 6, 2024.
Key Points:
- VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its fourth quarter 2023 financial results after market close on March 6, 2024.
- Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on March 6, 2024 at 4:30 pm Eastern Standard Time (EST).
Retrieved on:
Thursday, February 8, 2024
Standard of care,
Immunotherapy,
Amgen,
Prostate cancer,
Research,
SITC,
Society,
Patient,
ESSA,
FDA,
Publication,
Biomarker,
Doctor of Philosophy,
NanoString Technologies,
Therapy,
Drug development,
Biogen,
Journal,
University,
Puma Biotechnology Dr. Cesano succeeds Dr. Kenneth Hillan, who will step down effective today after a successful 7-year tenure as a director of Zymeworks.
Key Points:
- Dr. Cesano succeeds Dr. Kenneth Hillan, who will step down effective today after a successful 7-year tenure as a director of Zymeworks.
- “Zymeworks is honored to welcome Dr. Cesano to our board of directors,” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks.
- She joins three other new directors appointed in 2023: Mr. Derek Miller, Mr. Carlos Campoy, and Dr. Nancy Davidson.”
“The Zymeworks board of directors is sincerely grateful to Dr. Hillan for his dedicated service and significant contributions to the board.
- Dr. Cesano was also appointed to serve as a member of the research and development committee and nominating and corporate governance committee of the board of directors.
